The global dermal fillers market size accounted for USD 7.01 billion in 2024, grew to USD 7.60 billion in 2025 and is predicted to surpass around USD 15.71 billion by 2034, representing a healthy CAGR of 8.40% between 2024 and 2034. The North America dermal fillers market size is calculated at USD 2.52 billion in 2024 and is expected to grow at a fastest CAGR of 8.52% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Dermal Fillers Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Dermal Fillers Market, by Material, 2024-2034
8.1.1. Hyaluronic acid
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Calcium hydroxyl apatite
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Poly-L-lactic Acid
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. PMMA (Poly(methyl methacrylate))
8.1.4.1. Market Revenue and Forecast (2021-2034)
8.1.5. Fat Fillers
8.1.5.1. Market Revenue and Forecast (2021-2034)
8.1.6. Others
8.1.6.1. Market Revenue and Forecast (2021-2034)
9.1. Dermal Fillers Market, by Product, 2024-2034
9.1.1. Non-biodegradable
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Biodegradable
9.1.2.1. Market Revenue and Forecast (2021-2034)
10.1. Dermal Fillers Market, by Drug Type, 2024-2034
10.1.1. Branded
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Generic
10.1.2.1. Market Revenue and Forecast (2021-2034)
11.1. Dermal Fillers Market, by Application, 2024-2034
11.1.1. Wrinkle Correction Treatment
11.1.1.1. Market Revenue and Forecast (2021-2034)
11.1.2. Scar treatment
11.1.2.1. Market Revenue and Forecast (2021-2034)
11.1.3. Lip enhancement
11.1.3.1. Market Revenue and Forecast (2021-2034)
11.1.4. Restoration of volume
11.1.4.1. Market Revenue and Forecast (2021-2034)
11.1.5. Others
11.1.5.1. Market Revenue and Forecast (2021-2034)
12.1. Dermal Fillers Market, by End User, 2024-2034
12.1.1. Specialty and Dermatology Clinics
12.1.1.1. Market Revenue and Forecast (2021-2034)
12.1.2. Clinics and Hospitals
12.1.2.1. Market Revenue and Forecast (2021-2034)
12.1.3. Others
12.1.3.1. Market Revenue and Forecast (2021-2034)
12.1.4. OSAT
13.1. North America
13.1.1. Market Revenue and Forecast, by Material (2021-2034)
13.1.2. Market Revenue and Forecast, by Product (2021-2034)
13.1.3. Market Revenue and Forecast, by Drug Type (2021-2034)
13.1.4. Market Revenue and Forecast, by Application (2021-2034)
13.1.5. Market Revenue and Forecast, by End User (2021-2034)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Material (2021-2034)
13.1.6.2. Market Revenue and Forecast, by Product (2021-2034)
13.1.6.3. Market Revenue and Forecast, by Drug Type (2021-2034)
13.1.6.4. Market Revenue and Forecast, by Application (2021-2034)
13.1.6.5. Market Revenue and Forecast, by End User (2021-2034)
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Material (2021-2034)
13.1.7.2. Market Revenue and Forecast, by Product (2021-2034)
13.1.7.3. Market Revenue and Forecast, by Drug Type (2021-2034)
13.1.7.4. Market Revenue and Forecast, by Application (2021-2034)
13.1.7.5. Market Revenue and Forecast, by End User (2021-2034)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Material (2021-2034)
13.2.2. Market Revenue and Forecast, by Product (2021-2034)
13.2.3. Market Revenue and Forecast, by Drug Type (2021-2034)
13.2.4. Market Revenue and Forecast, by Application (2021-2034)
13.2.5. Market Revenue and Forecast, by End User (2021-2034)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Material (2021-2034)
13.2.6.2. Market Revenue and Forecast, by Product (2021-2034)
13.2.6.3. Market Revenue and Forecast, by Drug Type (2021-2034)
13.2.7. Market Revenue and Forecast, by Application (2021-2034)
13.2.8. Market Revenue and Forecast, by End User (2021-2034)
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Material (2021-2034)
13.2.9.2. Market Revenue and Forecast, by Product (2021-2034)
13.2.9.3. Market Revenue and Forecast, by Drug Type (2021-2034)
13.2.10. Market Revenue and Forecast, by Application (2021-2034)
13.2.11. Market Revenue and Forecast, by End User (2021-2034)
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Material (2021-2034)
13.2.12.2. Market Revenue and Forecast, by Product (2021-2034)
13.2.12.3. Market Revenue and Forecast, by Drug Type (2021-2034)
13.2.12.4. Market Revenue and Forecast, by Application (2021-2034)
13.2.13. Market Revenue and Forecast, by End User (2021-2034)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Material (2021-2034)
13.2.14.2. Market Revenue and Forecast, by Product (2021-2034)
13.2.14.3. Market Revenue and Forecast, by Drug Type (2021-2034)
13.2.14.4. Market Revenue and Forecast, by Application (2021-2034)
13.2.15. Market Revenue and Forecast, by End User (2021-2034)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Material (2021-2034)
13.3.2. Market Revenue and Forecast, by Product (2021-2034)
13.3.3. Market Revenue and Forecast, by Drug Type (2021-2034)
13.3.4. Market Revenue and Forecast, by Application (2021-2034)
13.3.5. Market Revenue and Forecast, by End User (2021-2034)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Material (2021-2034)
13.3.6.2. Market Revenue and Forecast, by Product (2021-2034)
13.3.6.3. Market Revenue and Forecast, by Drug Type (2021-2034)
13.3.6.4. Market Revenue and Forecast, by Application (2021-2034)
13.3.7. Market Revenue and Forecast, by End User (2021-2034)
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Material (2021-2034)
13.3.8.2. Market Revenue and Forecast, by Product (2021-2034)
13.3.8.3. Market Revenue and Forecast, by Drug Type (2021-2034)
13.3.8.4. Market Revenue and Forecast, by Application (2021-2034)
13.3.9. Market Revenue and Forecast, by End User (2021-2034)
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Material (2021-2034)
13.3.10.2. Market Revenue and Forecast, by Product (2021-2034)
13.3.10.3. Market Revenue and Forecast, by Drug Type (2021-2034)
13.3.10.4. Market Revenue and Forecast, by Application (2021-2034)
13.3.10.5. Market Revenue and Forecast, by End User (2021-2034)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Material (2021-2034)
13.3.11.2. Market Revenue and Forecast, by Product (2021-2034)
13.3.11.3. Market Revenue and Forecast, by Drug Type (2021-2034)
13.3.11.4. Market Revenue and Forecast, by Application (2021-2034)
13.3.11.5. Market Revenue and Forecast, by End User (2021-2034)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Material (2021-2034)
13.4.2. Market Revenue and Forecast, by Product (2021-2034)
13.4.3. Market Revenue and Forecast, by Drug Type (2021-2034)
13.4.4. Market Revenue and Forecast, by Application (2021-2034)
13.4.5. Market Revenue and Forecast, by End User (2021-2034)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Material (2021-2034)
13.4.6.2. Market Revenue and Forecast, by Product (2021-2034)
13.4.6.3. Market Revenue and Forecast, by Drug Type (2021-2034)
13.4.6.4. Market Revenue and Forecast, by Application (2021-2034)
13.4.7. Market Revenue and Forecast, by End User (2021-2034)
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Material (2021-2034)
13.4.8.2. Market Revenue and Forecast, by Product (2021-2034)
13.4.8.3. Market Revenue and Forecast, by Drug Type (2021-2034)
13.4.8.4. Market Revenue and Forecast, by Application (2021-2034)
13.4.9. Market Revenue and Forecast, by End User (2021-2034)
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Material (2021-2034)
13.4.10.2. Market Revenue and Forecast, by Product (2021-2034)
13.4.10.3. Market Revenue and Forecast, by Drug Type (2021-2034)
13.4.10.4. Market Revenue and Forecast, by Application (2021-2034)
13.4.10.5. Market Revenue and Forecast, by End User (2021-2034)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Material (2021-2034)
13.4.11.2. Market Revenue and Forecast, by Product (2021-2034)
13.4.11.3. Market Revenue and Forecast, by Drug Type (2021-2034)
13.4.11.4. Market Revenue and Forecast, by Application (2021-2034)
13.4.11.5. Market Revenue and Forecast, by End User (2021-2034)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Material (2021-2034)
13.5.2. Market Revenue and Forecast, by Product (2021-2034)
13.5.3. Market Revenue and Forecast, by Drug Type (2021-2034)
13.5.4. Market Revenue and Forecast, by Application (2021-2034)
13.5.5. Market Revenue and Forecast, by End User (2021-2034)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Material (2021-2034)
13.5.6.2. Market Revenue and Forecast, by Product (2021-2034)
13.5.6.3. Market Revenue and Forecast, by Drug Type (2021-2034)
13.5.6.4. Market Revenue and Forecast, by Application (2021-2034)
13.5.7. Market Revenue and Forecast, by End User (2021-2034)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Material (2021-2034)
13.5.8.2. Market Revenue and Forecast, by Product (2021-2034)
13.5.8.3. Market Revenue and Forecast, by Drug Type (2021-2034)
13.5.8.4. Market Revenue and Forecast, by Application (2021-2034)
13.5.8.5. Market Revenue and Forecast, by End User (2021-2034)
14.1. AbbVie, Inc.
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. HUADONG MEDICINE CO., LTD
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. BIOPLUS CO., LTD.
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. TEOXANE LABORATORIES
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. BIOHA LABORATORIES
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Prollenium Medical Technologies
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Galderma
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Merz Pharma
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Suneva Medical
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. BIOXIS pharmaceuticals
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample